5 of the Best New Stocks of Q2 2014

These IPO hits have run off returns of more than 70% in just a few short months

       

Best New Stocks of Q2 – #2, Vital Therapies (VTL)

vital therapies 185 5 of the Best New Stocks of Q2 2014Return: 129%

Vital Therapies’ (VTL) product is the ELAD System, which is a cell-based bio-artificial liver support system that operates outside a person’s body and helps to regenerate the patient’s liver. Even if the liver does not become healthy, ELAD will provide more time for a transplant — important considering the long waiting lines for such a procedure.

The drug has received the orphan designation in the U.S. and Europe (acute liver disease impacts at least 60,000 per year). This means the company is eligible for valuable tax credits as well as seven years of market exclusivity in the U.S. and 10 years in Europe.

Vital currently is enrolling patients for Phase 3 clinical trials.

Next Page


Article printed from InvestorPlace Media, http://investorplace.com/ipo-playbook/5-best-new-stocks-ipos/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.